BR0306444A - Uso de anticorpos anti-tnf(alfa) e outra droga - Google Patents

Uso de anticorpos anti-tnf(alfa) e outra droga

Info

Publication number
BR0306444A
BR0306444A BR0306444-1A BR0306444A BR0306444A BR 0306444 A BR0306444 A BR 0306444A BR 0306444 A BR0306444 A BR 0306444A BR 0306444 A BR0306444 A BR 0306444A
Authority
BR
Brazil
Prior art keywords
antibodies
tnf
another drug
alpha
human antibodies
Prior art date
Application number
BR0306444-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Steven Fischkoff
Elliot Chartash
Original Assignee
Abbott Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29268783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0306444(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Biotech Ltd filed Critical Abbott Biotech Ltd
Publication of BR0306444A publication Critical patent/BR0306444A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
BR0306444-1A 2002-04-26 2003-04-24 Uso de anticorpos anti-tnf(alfa) e outra droga BR0306444A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/133,715 US20030206898A1 (en) 2002-04-26 2002-04-26 Use of anti-TNFalpha antibodies and another drug
PCT/US2003/012976 WO2004004633A2 (fr) 2002-04-26 2003-04-24 Utilisation d'anticorps anti-tnf$g(a) et d'un autre produit pharmaceutique

Publications (1)

Publication Number Publication Date
BR0306444A true BR0306444A (pt) 2004-10-26

Family

ID=29268783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306444-1A BR0306444A (pt) 2002-04-26 2003-04-24 Uso de anticorpos anti-tnf(alfa) e outra droga

Country Status (18)

Country Link
US (1) US20030206898A1 (fr)
EP (3) EP2347766A1 (fr)
JP (2) JP2005523946A (fr)
KR (1) KR20100106631A (fr)
CN (3) CN1649624A (fr)
AR (2) AR039656A1 (fr)
AU (2) AU2003278692B2 (fr)
BR (1) BR0306444A (fr)
CA (1) CA2385777A1 (fr)
IL (2) IL164759A0 (fr)
MX (1) MXPA04010498A (fr)
NZ (1) NZ560793A (fr)
PE (1) PE20040474A1 (fr)
PL (1) PL373333A1 (fr)
TW (2) TWI353851B (fr)
UY (1) UY27780A1 (fr)
WO (1) WO2004004633A2 (fr)
ZA (1) ZA200408509B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
PL218992B1 (pl) * 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
PL1799230T3 (pl) * 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
WO2006041970A2 (fr) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Infection a virus respiratoire syncytial (rsv)
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
PT1948235E (pt) 2005-11-01 2013-11-26 Abbvie Biotechnology Ltd Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores
EP2738179A1 (fr) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Purification d'anticorps
WO2007120656A2 (fr) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2012586A4 (fr) 2006-04-10 2010-08-18 Abbott Biotech Ltd Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
EP2666472A3 (fr) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite psoriasique
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
TWI498137B (zh) 2006-06-30 2015-09-01 Abbvie Biotechnology Ltd 自動注射裝置
NZ613356A (en) 2006-10-27 2015-02-27 Abbvie Biotechnology Ltd Crystalline anti-htnfalpha antibodies
US8092998B2 (en) * 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
WO2008150490A2 (fr) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Compositions et utilisations pour le traitement du psoriasis et de la maladie de crohn
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
CA2693771A1 (fr) * 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Compositions et methodes d'administration pulmonaire d'un inhibiteur du tnf.alpha.
WO2009020654A1 (fr) 2007-08-08 2009-02-12 Abbott Laboratories Compositions et procédés permettant la cristallisation d'anticorps
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
BRPI0819971A2 (pt) * 2007-12-06 2017-06-27 Burnham Institute For Medical Res anticorpos contra vírus influenza e métodos de seu uso
CA2710333A1 (fr) * 2008-01-03 2009-07-09 Abbott Biotechnology Ltd. Prediction de l'efficacite a long terme d'un compose dans le traitement du psoriasis
EP2249809A1 (fr) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Composition de protéine pulvérisée et procédés de fabrication de celle-ci
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (fr) 2008-06-03 2016-04-06 AbbVie Inc. Immunoglobulines à deux domaines variables et leurs utilisations
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20100016265A1 (en) * 2008-07-16 2010-01-21 Qaiser Yusuf Anti-inflammatory composition and method for preparation
AU2010236256C1 (en) 2009-04-16 2015-10-22 Abbvie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
AR078254A1 (es) * 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012004415A (es) * 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8758301B2 (en) 2009-12-15 2014-06-24 Abbvie Biotechnology Ltd Firing button for automatic injection device
PH12012501991A1 (en) * 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
CA2801917C (fr) 2010-06-03 2017-04-25 Abbvie Biotechnology Ltd Utilisations et compositions pour le traitement de l'hidrosadenite (hs)
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
RU2602039C2 (ru) 2011-01-24 2016-11-10 Эббви Байотекнолоджи Лтд. Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
WO2012121403A1 (fr) * 2011-03-07 2012-09-13 The University Of Tokushima Procédé de traitement de la sclérose latérale amyotrophique
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
MX2015003007A (es) 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
LT2897978T (lt) 2012-09-19 2017-06-12 Abbvie Biotherapeutics Inc. Antikūnų su sumažintu imunogeniškumu identifikavimo būdas
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2769736A1 (fr) * 2013-02-22 2014-08-27 Bill, Anja Composition pharmaceutique pour le traitement du syndrome de burn-out
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP2970459A2 (fr) 2013-03-15 2016-01-20 AbbVie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (fr) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CA2985816A1 (fr) * 2015-05-15 2016-11-24 The General Hospital Corporation Anticorps antagonistes de la superfamille du recepteur du facteur de necrose anti-tumoral
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
EP3439691A4 (fr) * 2016-04-04 2020-05-13 GU Ventures AB Méthodes et compositions pour le traitement de l'hernie du disque intervertébral
WO2017184880A1 (fr) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. Procédé de remplissage d'un récipient sans espace libre
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CN106918633B (zh) * 2017-04-24 2019-06-25 中国科学院苏州生物医学工程技术研究所 基于适体和金磁纳米颗粒的细胞因子TNF-α的检测方法
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
CN111755070A (zh) * 2019-03-29 2020-10-09 中山大学 一种基于级联判决系统的CircRNA功能预测方法
TW202228775A (zh) 2020-10-14 2022-08-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物及方法
CN116635024A (zh) * 2020-10-14 2023-08-22 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
EP0230574A3 (fr) 1986-01-31 1989-03-22 Yale University Compositions pharmaceutiques contre les infections dues au virus LAV/HTLV-III et leur application
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2096553T3 (es) 1988-12-19 1997-03-16 American Cyanamid Co Metodo para el tratamiento de choque endotoxico en un animal mamifero.
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
AU646695B2 (en) 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
DE4037604A1 (de) 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992003145A1 (fr) 1990-08-27 1992-03-05 Peptide Technology Ltd. Procede de traitement des infections virales
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
CA2736076A1 (fr) 1991-03-18 1992-09-19 New York University Anticorps monoclonaux et chimeriques specifiques du facteur de necrose tumorale humain
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
WO1993011793A1 (fr) 1991-12-17 1993-06-24 Schering Corporation Utilisation de la combinaison du facteur de necrose anti-tumeur et de l'interleukine-6 dans le traitement du choc septique
US5605923A (en) 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
ES2121907T3 (es) 1992-08-28 1998-12-16 Bayer Ag Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU682156B2 (en) 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
EP0614984B2 (fr) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anticorps monoclonaux humains anti-TNF alpha
DE4307508A1 (de) 1993-03-10 1994-09-15 Knoll Ag Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
US5574022A (en) 1994-04-14 1996-11-12 The Center For Innovative Technology Method of attenuating physical damage to the spinal cord
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
JP2002509109A (ja) * 1998-01-19 2002-03-26 ディーシーヴィー インコーポレイテッド 関節炎および／または自己免疫疾患を治療および予防するための組成物および方法
AU2372400A (en) * 1999-01-19 2000-08-07 Dcv, Inc. Egg anti-inflammatory composition and method of treating and preventing inflammation
WO2001000229A1 (fr) * 1999-06-24 2001-01-04 Pharmacia Corporation Combinaison d'antagonistes du facteur de necrose des tumeurs (tnf) et d'inhibiteurs de cox-2 pour le traitement des inflammations
WO2001037874A2 (fr) * 1999-11-24 2001-05-31 Centocor, Inc. Traitement du psoriasis
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
CA2817619A1 (fr) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.

Also Published As

Publication number Publication date
KR20100106631A (ko) 2010-10-01
IL209010A0 (en) 2011-01-31
JP2005523946A (ja) 2005-08-11
EP2196218A2 (fr) 2010-06-16
CN1649624A (zh) 2005-08-03
UY27780A1 (es) 2003-11-28
IL164759A0 (en) 2005-12-18
CA2385777A1 (fr) 2003-10-14
CN101890163A (zh) 2010-11-24
TW201138826A (en) 2011-11-16
AR077473A2 (es) 2011-08-31
WO2004004633A3 (fr) 2004-06-10
TW200401647A (en) 2004-02-01
MXPA04010498A (es) 2004-12-13
AR039656A1 (es) 2005-03-02
AU2009200817A1 (en) 2009-03-26
NZ560793A (en) 2009-11-27
AU2003278692B2 (en) 2009-04-09
PE20040474A1 (es) 2004-08-12
EP1501545A4 (fr) 2006-08-09
EP2196218A3 (fr) 2010-07-07
AU2003278692A1 (en) 2004-01-23
EP2347766A1 (fr) 2011-07-27
EP1501545A2 (fr) 2005-02-02
PL373333A1 (pl) 2005-08-22
JP2010248199A (ja) 2010-11-04
ZA200408509B (en) 2006-06-28
CN101229371A (zh) 2008-07-30
US20030206898A1 (en) 2003-11-06
TWI353851B (en) 2011-12-11
WO2004004633A2 (fr) 2004-01-15

Similar Documents

Publication Publication Date Title
BR0206289A (pt) Processos de administração de anticorpos anti-tnf(alfa)
UY27780A1 (es) Uso de anticuerpos anti-tnf alfa y otro fármaco
Svenson et al. Specific binding of interleukin 1 (IL-1) β and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
PE20021151A1 (es) Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de racientes anemicos
MXPA05007823A (es) Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes.
EE05496B1 (et) Antikeha, mis seob osteoprotegeriini siduvat valku
AR040603A1 (es) El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
BRPI0412890A (pt) método de tratar uma doença em um indivìduo humano em necessidade do mesmo, composição farmacêutica, e, métodos de selecionar um composto para administração conjuntamente com um anticorpo terapêutico, e de aumentar a eficiência de um tratamento envolvendo a administração de um anticorpo terapêutico que pode ser ligado por cd16 em um indivìduo
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
BR9710811A (pt) Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
ES2102007T3 (es) Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
BRPI0516260A (pt) antagonista de fator de necrose tumoral 1, ligante, monÈmero de anticorpo de domìnio (dab), ácido nucleico, vetor, célula hospedeira, métodos para produzir um polipeptìdeo, um monÈmero de dab, um ligante multiespecìfico, e um formato de anticorpo, e para tratar, suprimir ou prevenir uma doença, composição, uso de um antagonista, formato de anticorpo, polipeptìdeo, e, anticorpo ou fragmento de ligação de antìgeno do mesmo
WO2002083171A3 (fr) Traitement du cancer par utilisation d'anticorps specifiques de la fap-alpha
BR0209177A (pt) Anticorpo especìfico a tumor recombinante e uso do mesmo
EE05212B1 (et) Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
ATE235551T1 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen
BR112022003498A2 (pt) Peptídeos recombinantes do tipo elastina imunotolerantes e métodos de uso
UA88604C2 (ru) Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания
Wunder et al. THU0107 Methotrexate covalently coupled to human serum albumin (mtx-hsa) targets to inflamed joints and is superior to methotrexate inhibiting the development of murine collagen-induced arthritis (cia)
UY27323A1 (es) Métodos para administrar anticuerpos anti-tnfa
CY1113904T1 (el) Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.